Tunali et al. analyzed pre-immunotherapy data from NSCLC patients treated with PD-1/PD-L1 from 13 institutions, finally identifying four radiomic features that were used for the construction of a model for the differentiation of patient response to ICI with an AUC of 0.790 [68]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.